ライフサイエンスコーパス: lipopolysaccharide-binding protein

1 se:mannitol test, plasma zonulin, and plasma lipopolysaccharide-binding protein).

2 rred in reverse from MD-2 to CD14 but not to lipopolysaccharide-binding protein.

3 Levels of the serum opsonin lipopolysaccharide-binding protein also significantly in

4 prevents interaction of endotoxin with both lipopolysaccharide binding protein and CD14, thereby blo

5 Subgroup analyses on patients with increased lipopolysaccharide binding protein and systemic vascular

6 ity of two other proteins known to bind LPS, lipopolysaccharide-binding protein and bactericidal/perm

7 dging endotoxin (E) recognition initiated by lipopolysaccharide-binding protein and CD14 to TLR4 acti

8 For all aggregates, lipopolysaccharide-binding protein and soluble CD14-indu

9 oxin from an aggregated form to CD14 via the lipopolysaccharide-binding protein and then to MD-2.

10 nding of LPS to its plasma carrier molecule, lipopolysaccharide binding protein, and decreased bindin

11 as measured by soluble CD14, soluble CD163, lipopolysaccharide binding protein, and microbial 16s ri

12 Lipopolysaccharide-binding protein augmented the release

13 of peripheral blood mononuclear cells, since lipopolysaccharide-binding protein augments release in a

14 n and protein-protein interactions involving lipopolysaccharide-binding protein, CD14, MD-2, and Toll

15 n and protein-protein interactions involving lipopolysaccharide-binding protein, CD14, MD-2, and Toll

16 ion, a single nucleotide polymorphism in the lipopolysaccharide binding protein coding region that wa

17 erleukin-6, tumor necrosis factor-alpha, and lipopolysaccharide binding protein decreased significant

18 rphisms in the proximal coding region of the lipopolysaccharide binding protein gene and to determine

19 ein (PLTP) are members of the lipid transfer/lipopolysaccharide binding protein gene family.

20 As a member of the lipid-transfer lipopolysaccharide-binding protein gene family, phosphol

21 The recent characterization of lipopolysaccharide binding protein (LBP) and bactericida

22 n (lipopolysaccharide, LPS) are amplified by lipopolysaccharide binding protein (LBP) and CD14, resul

23 f phospholipids, apolipoprotein A-I (apoAI), lipopolysaccharide binding protein (LBP) and Factor H-re

24 dal/permeability inducing protein (BPI), and lipopolysaccharide binding protein (LBP) are members of

25 Lipopolysaccharide binding protein (LBP) function is dep

26 elevated levels of soluble CD14 (sCD14) and lipopolysaccharide binding protein (LBP) in the plasma d

27 Lipopolysaccharide binding protein (LBP) is a plasma pro

28 flammatory and anti-inflammatory markers and lipopolysaccharide binding protein (LBP) plasma as well

29 genomic screen, we found that expression of lipopolysaccharide binding protein (LBP), a member of th

30 x of complement activation; plasma levels of lipopolysaccharide binding protein (LBP), an acute phase

31 trations of HDL-bound serum amyloid A (SAA), lipopolysaccharide binding protein (LBP), apolipoprotein

32 Complement C5A anaphylatoxin (C5A), lipopolysaccharide binding protein (LBP), C-reactive pro

33 nd plasma levels of an acute phase reactant, lipopolysaccharide binding protein (LBP), to clinical ou

34 Lipopolysaccharide-binding protein (LBP) and CD14 play k

35 Serum levels of lipopolysaccharide-binding protein (LBP) and IL-10 were

36 by two lipid-binding serum proteins known as lipopolysaccharide-binding protein (LBP) and soluble CD1

37 ieved to involve the interaction of LPS with lipopolysaccharide-binding protein (LBP) in the serum an

38 Plasma endotoxin and lipopolysaccharide-binding protein (LBP) levels were mea

39 In this study, we examined the role of lipopolysaccharide-binding protein (LBP), a protein impo

40 dotoxin (E) with endotoxin-binding proteins (lipopolysaccharide-binding protein (LBP), CD14, and MD-2

41 negative bacteria require the interaction of lipopolysaccharide-binding protein (LBP), CD14, Toll-lik

42 Levels of soluble CD14 (sCD14), human lipopolysaccharide-binding protein (LBP), immunoglobulin

43 al/permeability-increasing protein (BPI) and lipopolysaccharide-binding protein (LBP), which are cent

44 of endotoxin have revealed the importance of lipopolysaccharide-binding protein (LBP)-dependent extra

45 dicated by the regularisation of clotting by lipopolysaccharide-binding protein (LBP).

46 te that albumin is an essential component of lipopolysaccharide binding protein- (LBP) and sCD14-depe

47 protein 1 levels (r = 0.396, P = .0002) and lipopolysaccharide binding protein levels (r = 0.25, P =

48 Phospholipid transfer protein (PLTP) and lipopolysaccharide-binding protein (LPB) are lipid trans

49 tein (LBP) are members of the lipid transfer/lipopolysaccharide binding protein (LT/LBP) family of pr

50 on of IL-6 messenger RNA (mRNA) in liver and lipopolysaccharide binding protein mRNA in the liver and

51 trations of gut-derived hormones, incretins, lipopolysaccharide-binding protein, or other markers of

52 or-alpha (P<.05), interleukin-6 (P<.05), and lipopolysaccharide binding protein (P<.05) levels were a

53 on rate (P<.05), interleukin-6 (P<.005), and lipopolysaccharide binding protein (P<.05).

54 the release of secretory phospholipase A2 or lipopolysaccharide-binding protein (P > .05).

55 lavage co-precipitates CD14, a cell surface lipopolysaccharide-binding protein that is involved in i

56 ration rate and plasma renin, noradrenaline, lipopolysaccharide binding protein, troponin T, and brai

57 a, interleukin 6 (IL-6), interleukin 10, and lipopolysaccharide binding protein were assessed preoper

58 Originally identified as a lipopolysaccharide binding protein with Gram-negative ba